Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Soo Lim, Jin‐Wook Kim, Giovanni Targher
Trends in Endocrinology and Metabolism (2021) Vol. 32, Iss. 7, pp. 500-514
Closed Access | Times Cited: 151

Showing 1-25 of 151 citing articles:

Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 569
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
Donghee Kim, Peter Konyn, Keeryth K. Sandhu, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 6, pp. 1284-1291
Closed Access | Times Cited: 333
Human microbiome and metabolic health: An overview of systematic reviews
Nathalie Michels, Semi Zouiouich, Bert Vanderbauwhede, et al.
Obesity Reviews (2022) Vol. 23, Iss. 4
Open Access | Times Cited: 83
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?
Mariana M. Ramírez-Mejía, Carlos Jiménez-Gutiérrez, Mohammed Eslam, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 168-178
Closed Access | Times Cited: 54
The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders
Binbin Zhang, Minjie Jiang, Jianan Zhao, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 61
Progress in Nonalcoholic Fatty Liver Disease: SIRT Family Regulates Mitochondrial Biogenesis
Chuanfei Zeng, Mingkai Chen
Biomolecules (2022) Vol. 12, Iss. 8, pp. 1079-1079
Open Access | Times Cited: 49
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 6, pp. 424-442
Closed Access | Times Cited: 47
Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies
Francesco Bellinato, Paolo Gisondi, Alessandro Mantovani, et al.
Journal of Endocrinological Investigation (2022) Vol. 45, Iss. 7, pp. 1277-1288
Open Access | Times Cited: 41
Waist Circumference Is an Essential Factor in Predicting Insulin Resistance and Early Detection of Metabolic Syndrome in Adults
José Ignacio Ramírez‐Manent, Andrés Martínez Jover, Caroline Silveira Martinez, et al.
Nutrients (2023) Vol. 15, Iss. 2, pp. 257-257
Open Access | Times Cited: 40
The Potential Cardiometabolic Effects of Long-Chain ω-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies
Jae Hyun Bae, Hyunjung Lim, Soo Lim
Advances in Nutrition (2023) Vol. 14, Iss. 4, pp. 612-628
Open Access | Times Cited: 36
Steatotic liver disease, MASLD and risk of chronic kidney disease
Josh Bilson, Alessandro Mantovani, Christopher D. Byrne, et al.
Diabetes & Metabolism (2023) Vol. 50, Iss. 1, pp. 101506-101506
Open Access | Times Cited: 35
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
Muthukumaran Jayachandran, Shen Qu
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 6, pp. 1189-1204
Closed Access | Times Cited: 31
20-Year Trends in Metabolic Syndrome Among Korean Adults From 2001 to 2020
Dahyun Park, Min‐Jeong Shin, Jean‐Pierre Després, et al.
JACC Asia (2023) Vol. 3, Iss. 3, pp. 491-502
Open Access | Times Cited: 24
Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic
Guocheng Rao, Xi Peng, Xinqiong Li, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 24
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Yumin Wang, Joshua S. Fleishman, Tongda Li, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Khamis Al-Hashmi, Rosaria Vincenza Giglio, Anca Pantea Stoian, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 10
Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
Anna Alisi, Geoffrey W. McCaughan, Henning Grønbæk
Hepatology International (2024) Vol. 18, Iss. S2, pp. 861-872
Closed Access | Times Cited: 8
Non-Alcoholic Fatty Liver Disease (NAFLD) and Potential Links to Depression, Anxiety, and Chronic Stress
Sue Shea, Christos Lionis, Chris Kite, et al.
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1697-1697
Open Access | Times Cited: 53
Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation
Junzhao Ye, Xiaodong Zhuang, Xin Li, et al.
Metabolism (2022) Vol. 136, pp. 155294-155294
Open Access | Times Cited: 36
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
Mark Muthiah, Cheng Han Ng, Kai En Chan, et al.
Annals of Hepatology (2022) Vol. 28, Iss. 1, pp. 100762-100762
Open Access | Times Cited: 36
Associations Between GGT/HDL and MAFLD: A Cross-Sectional Study
Yuling Xing, Jinhu Chen, Jing Liu, et al.
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 383-394
Open Access | Times Cited: 33
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 32
Di-(2-ethylhexyl) phthalate increases plasma glucose and induces lipid metabolic disorders via FoxO1 in adult mice
Xiangjuan Wei, Daqian Yang, Boya Zhang, et al.
The Science of The Total Environment (2022) Vol. 842, pp. 156815-156815
Closed Access | Times Cited: 31
Natural products targeting inflammation-related metabolic disorders: A comprehensive review
Firzan Nainu, Andri Frediansyah, Sukamto S. Mamada, et al.
Heliyon (2023) Vol. 9, Iss. 6, pp. e16919-e16919
Open Access | Times Cited: 21
Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness
Pegah Golabi, Isakov Va, Zobair M. Younossi
Clinics in Liver Disease (2023) Vol. 27, Iss. 2, pp. 173-186
Closed Access | Times Cited: 18
Page 1 - Next Page

Scroll to top